To report an adverse event or product quality issue, please email us at reportnow@argenx.com or call us at 1-833-274-9411.
©2026 argenx | Disclaimer | Privacy Policy | Regulations | U.S. Supplemental Privacy Notice
How We Bring Entrepreneurial Science to Life
At argenx, curiosity is the catalyst for innovation.
Who We Are
The People and Principles Behind Our Ambition
Our culture and our entrepreneurial spirit define us. Each of us plays a part in pursuing bold pathways over conventional ones, working together to deliver real change in people’s lives.
Innovation
Bold Pathways in Immunology
Every day, we are inspired by the strength of people facing complex diseases. Their resilience pushes us to move immunology science faster than once thought possible, as we seek to co-create potential life-changing treatments.
The infinity sign symbolizes our commitment to science and patients. It has no bounds.
Diseases & Patients
For People Who Can’t Keep Waiting
Each day at argenx, we work to advance the understanding of diseases where better treatment options are urgently needed. Our ambition is to discover breakthroughs and deliver tomorrow’s medicines for the people who need them today.
Patient Voices
Behind every diagnosis is a person navigating a life-changing disease. These are their stories, in their own words.
“At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion…because at least there was a name to what I had.”
Jamilah
Living With CIDP
“Early on I learned that this disease is just as mental as it is physical.”
Melissa
Living With Myositis
“When I was younger they told me I would never walk again, but I grew up playing basketball...”
Eri
Living With MG
“When I started receiving treatment, it was hard for me not knowing when I would lose motor functions, or even what tomorrow might bring.”
Mihoko
Living With MG
- Slide 1
- Slide 2
- Slide 3
- Slide 4
Our Pipeline
Products and Candidates
Our product portfolio meets patients where they need us most and seeks to expand what’s possible for them. Our team works alongside scientists, physicians, and academic researchers as a co-creation force with shared ambition to broaden opportunities for patients.
Efgartigimod
We are investigating efgartigimod for the treatment of several diseases that have been underserved. Efgartigimod is marketed as VYVGART® for the treatment of adults with generalized myasthenia gravis (gMG) and VYVGART® Hytrulo for the treatment of adults with gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Empasiprubart
We are evaluating empasiprubart for the treatment of long-overlooked IgM-driven autoimmune diseases.
Empasiprubart is designed to be a humanized sweeping antibody intended to inhibit the function of C2 and downstream complement activation.
Empasiprubart is not approved by any health authority for the treatment of any condition, as safety and efficacy have not been established.
Adimanebart
We are evaluating adimanebart for the treatment of neuromuscular diseases, including congenital myasthenic syndromes (CMS) and spinal muscular atrophy (SMA).
Adimanebart is a humanized monoclonal antibody designed to activate muscle-specific kinase (MuSK), a critical regulator of neuromuscular junction stability and function.
Adimanebart is not approved by any health authority for the treatment of any condition, as safety and efficacy have not been established.
Partnered Programs
Partnership Drives Innovation
We know we don‘t have all the answers. But we‘re committed to finding them. So we partner with experts to help us turn promising science into medicine for patients, faster.
Newsroom
Read Our Latest Updates
argenx Completes Acquisition of Forte Biosciences, Inc.
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Mark’s Story: Navigating Life with Ocular Myasthenia Gravis (oMG)
Understanding Congenital Myasthenic Syndromes: Rare, Complex, and Underserved
- 1
- 2
argenx Completes Acquisition of Forte Biosciences, Inc.
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Mark’s Story: Navigating Life with Ocular Myasthenia Gravis (oMG)
Understanding Congenital Myasthenic Syndromes: Rare, Complex, and Underserved
- Slide 1
- Slide 2
- Slide 3
- Slide 4
Join Us
Join Our Team
Curiosity is a job requirement at argenx. We’re looking for people who ask questions, want to be challenged, and seek to work differently. Together, we’re building a new approach to entrepreneurial science.
Explore More
At argenx, every piece of the innovation story connects. See where it leads next.
Immunology Innovation Program
Immunology Innovation Program (IIP) challenges conventions to deliver life-changing treatments.
Case Studies
Discover the science and stories of how we‘re helping to expand possibilities in immunology.
Press Releases
The latest news and press releases from argenx.
